APRE Message Board Post 9055214 | Aprea Therapeutics Inc.
home / stock / apre / apre message board
jlewis082022
(investorshub)
Posted on: Jun/16/2021 17:31:20
Source: investorshub
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164423124
Pump and dump pos imo??
News, Short Squeeze, Breakout and More Instantly...
-
DOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it will host a virtual KOL...
-
APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need Dosing of the first patient in the ACESOT-1051 study represent...
-
ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human efficacy data in 2H 2024 Through the first 5 cohorts, ATRN-119 has been fo...